Allergan | Search Results | Leaders in Pharmaceutical Business Intelligence (LPBI) Group

Search Results for 'Allergan'

From Thalidomide to Revlimid: Celgene to Bristol Myers to possibly Pfizer; A Curation of Deals, Discovery and the State of Pharma

Posted in Cancer - General, Cancer and Current Therapeutics, Drug Development Process, Health Economics and Outcomes Research, Patents, Pharmaceutical Industry Competitive Intelligence, Pharmaceutical R&D Investment, Uncategorized, tagged Bristol-Myers Squibb, Celgene, Drug Price Competition and Patent Term Restoration Act, health costs, Mergers and acquisitions, Multiple myeloma, Pfizer, pharma deals, Revlimid, thalidomide on January 25, 2019| Leave a Comment »

From Thalidomide to Revlimid: Celgene to Bristol Myers to possibly Pfizer; A Curation of Deals, Discovery and the State of Pharma Curator: Stephen J. Williams, Ph.D. Updated 6/24/2019 Updated 4/12/2019 Updated 2/28/2019 Lenalidomide (brand name Revlimid) is an approved chemotherapeutic used to treat multiple myeloma, mantle cell lymphoma, and certain myedysplastic syndromes. It is […]

Read Full Post »

M&A – New Rules in the Game: @Tulane University’s Law School, M&A Conference – Allergan Inc.’s $66 billion sale to Actavis PLC

Posted in Pharmaceutical Industry Competitive Intelligence, Pharmaceutical R&D Investment on March 30, 2015| Leave a Comment »

M&A – New Rules in the Game: @Tulane University’s Law School, M&A Conference – Allergan Inc.’s $66 billion sale to Actavis PLC Reporter: Aviva Lev-Ari, PhD, RN The deal, Allergan Inc.’s $66 billion sale to Actavis PLC, closed on 3/22/2015, ahead of schedule and 11 months after Valeant Pharmaceuticals International Inc. and activist William Ackman’s hedge-fund firm had […]

Read Full Post »

BioGENEius GenePool Competition – the “nature and nurture” SHARK TANK® at Bio International Convention, June 19-22, 2017 | San Diego, CA

Posted in BioTechnology - Venture Creation on June 22, 2017| Leave a Comment »

BioGENEius GenePool Competition – the “nature and nurture” SHARK TANK® at Bio International Convention, June 19-22, 2017 | San Diego, CA Reporter: Aviva Lev-Ari, PhD, RN http://www.convention.bio.org/2017/ AGENDA BIO 2017 Schedule Arrive Sunday and Stay Until Friday! Take full advantage of BIO 2017! Partnering and Education kick off on Monday afternoon, and the BIO […]

Read Full Post »

Re-Creation of the Big Pharma Model via Transformational Deals for Accelerating Innovations: Licensing vs In-house inventions

Posted in Pharmaceutical Analytics, Pharmaceutical Drug Discovery, Pharmaceutical Industry Competitive Intelligence, Pharmaceutical R&D Informatics, Pharmaceutical R&D Investment on July 27, 2015| Leave a Comment »

Re-Creation of the Big Pharma Model via Transformational Deals for Accelerating Innovations: Licensing vs In-house inventions Reporter: Aviva Lev-Ari, PhD, RN SOURCE http://www.wsj.com/articles/teva-to-buy-allergan-generics-for-40-5-billion-1437988044 Teva-Allergan Buy Likely Heralds More Big Deals Teva’s acquisition of Allergan’s generic-drugs unit for $40.5 billion is likely to trigger more deal-making in the already-frenzied health-care sector. Bernstein analyst Ronny Gal said […]

Read Full Post »

Allergan agrees to $66 billion Actavis offer $219 a share

Posted in Pharmaceutical Industry Competitive Intelligence on November 17, 2014| Leave a Comment »

Allergan agrees to $66 billion Actavis offer $219 a share Reporter: Aviva Lev-Ari, PhD, RN (Reuters) – Botox maker Allergan Inc on Monday accepted a $66 billion takeover bid from Actavis Plc, ending a seven-month hostile pursuit by activist investor William Ackman and Valeant Pharmaceuticals International Inc. Dublin-based Actavis offered $219 per share in cash and stock, amounting […]

Read Full Post »

Economic Potential of a Drug Invention (Prof. Zelig Eshhar, Weitzman Institute, registered the patent) versus a Cancer Drug in Clinical Trials: CAR-T as a Case in Point, developed by Kite Pharma, under Arie Belldegrun, CEO, acquired by Gilead for $11.9 billion, 8/2017.

Posted in BioTechnology - Venture Creation, BioTechnology - Venture Creation, Venture Capital, CANCER BIOLOGY & Innovations in Cancer Therapy, CAR-T, Immune Engineering, Immuno-Oncology & Genomics, Immunotherapy, Intellectual Property, Intellectual Property, Innovations, Commercialization, Investment in technological breakthrough, Interviews with Scientific Leaders, Patent Law in Biotech, Venture Capital on October 4, 2017| Leave a Comment »

Economic Potential of a Drug Invention (Prof. Zelig Eshhar, Weitzman Institute, registered the patent) versus a Cancer Drug in Clinical Trials: CAR-T as a Case in Point, developed by Kite Pharma, under Arie Belldegrun, CEO, acquired by Gilead for $11.9 billion, 8/2017. Curator: Aviva Lev-Ari, PhD, RN UPDATED on 2/21/2021 The Announcement of the 2021 […]

Read Full Post »

Two New Drugs for Inflammatory Bowel Syndrome Are Giving Patients Hope

Posted in Immunology, Immunotherapy, Inflammasome, Pharmaceutical Discovery, Pharmaceutical Drug Discovery, Pharmaceutical Industry Competitive Intelligence, tagged Actavis, Food and Drug Administration, guanylate cyclase, health, IBS, inflamation, inflammatory bowel disease (IBD), medicine, opiod delta agonist, plecanatide, Synergy Pharmaceuticals, Viberzi on January 7, 2016| Leave a Comment »

Two New Drugs for Inflammatory Bowel Syndrome Are Giving Patients Hope Reporter: Stephen J. Williams, Ph.D. Actavis Receives FDA Approval for VIBERZI (eluxadoline) for the Treatment of Irritable Bowel Syndrome with Diarrhea (IBS-D) in Adults -First in class treatment for IBS-D treats hallmark symptoms of IBS-D; abdominal pain and diarrhea DUBLIN, May 27, 2015 […]

Read Full Post »

C. botulinum toxin activity

Posted in Innovations in Neurophysiology & Neuropsychology, Intellectual Property, Innovations, Commercialization, Investment in technological breakthrough, Pain: Etiology, Genetics & Innovations in Treatment, Pharmaceutical Analytics, tagged botulinum toxin, mechanism of action, therapeutic use on December 12, 2015| Leave a Comment »

C. botulinum toxin activity Larry H. Bernstein, MD, FCAP, Curator LPBI The botulinum toxin as a therapeutic agent: molecular and pharmacological insights Roshan Kukreja,1 Bal Ram Singh2 Dove 8 Dec 2015; Volume 2015: 5: 173—183 DOI http://dx.doi.org/10.2147/RRBC.S60432 Botulinum neurotoxins (BoNTs), the most potent toxins known to mankind, are metalloproteases that act on nerve–muscle junctions […]